Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
46
IPHA Quote, Financials, Valuation and Earnings
Last price:
$2.06
Seasonality move
:
0.12%
Day range:
$2.03 - $2.10
52-week range:
$1.29 - $3.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.15x
P/B ratio:
5.35x
Volume:
48.4K
Avg. volume:
986.4K
1-year change:
-24.02%
Market cap:
$165.1M
Revenue:
$56.2M
EPS (TTM):
-$0.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IPHA
Innate Pharma SA
|
-- | -- | -- | -- | $7.25 |
|
CLLS
Cellectis SA
|
$9.1M | -$0.24 | 3346.52% | -69.12% | -- |
|
DBVT
DBV Technologies SA
|
$1.1M | -$1.77 | -- | -59.89% | -- |
|
GNFT
Genfit SA
|
-- | -- | -- | -- | -- |
|
IVA
Inventiva SA
|
$1.5M | -$0.56 | -- | -- | -- |
|
NBTX
Nanobiotix SA
|
-- | -- | -- | -- | $10.31 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IPHA
Innate Pharma SA
|
$2.04 | $7.25 | $165.1M | -- | $0.00 | 0% | 6.15x |
|
CLLS
Cellectis SA
|
$1.61 | -- | $161.2M | -- | $0.00 | 0% | 4.96x |
|
DBVT
DBV Technologies SA
|
$3.19 | -- | $65.4M | -- | $0.00 | 0% | -- |
|
GNFT
Genfit SA
|
$3.80 | -- | $189.6M | 33.72x | $0.00 | 0% | 2.75x |
|
IVA
Inventiva SA
|
$2.35 | -- | $123M | -- | $0.00 | 0% | 7.03x |
|
NBTX
Nanobiotix SA
|
$3.13 | $10.31 | $148.4M | -- | $0.00 | 0% | 3.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IPHA
Innate Pharma SA
|
55.22% | 1.864 | 24.23% | 2.76x |
|
CLLS
Cellectis SA
|
26.36% | 0.776 | 21.83% | 1.74x |
|
DBVT
DBV Technologies SA
|
-- | -0.249 | -- | -- |
|
GNFT
Genfit SA
|
-- | -0.225 | -- | -- |
|
IVA
Inventiva SA
|
-145.15% | 0.370 | 32.05% | 0.43x |
|
NBTX
Nanobiotix SA
|
195.9% | 1.177 | 20.12% | 1.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IPHA
Innate Pharma SA
|
-- | -- | -39.78% | -72.79% | -- | -- |
|
CLLS
Cellectis SA
|
-- | -$10.8M | -57.78% | -79.78% | -130.83% | -$6.6M |
|
DBVT
DBV Technologies SA
|
-- | -$30.3M | -- | -- | -- | -$22.9M |
|
GNFT
Genfit SA
|
-- | -- | -- | -- | -- | -- |
|
IVA
Inventiva SA
|
-- | -- | -- | -- | -- | -- |
|
NBTX
Nanobiotix SA
|
-- | -- | -161.14% | -- | -- | -- |
Innate Pharma SA vs. Competitors
-
Which has Higher Returns IPHA or CLLS?
Cellectis SA has a net margin of -- compared to Innate Pharma SA's net margin of -142.32%. Innate Pharma SA's return on equity of -72.79% beat Cellectis SA's return on equity of -79.78%.
Company Gross Margin Earnings Per Share Invested Capital IPHAInnate Pharma SA-- -- $68.9M CLLSCellectis SA-- -$0.23 $175.7M -
What do Analysts Say About IPHA or CLLS?
Innate Pharma SA has a consensus price target of $7.25, signalling upside risk potential of 263.33%. On the other hand Cellectis SA has an analysts' consensus of -- which suggests that it could grow by 314.08%. Given that Cellectis SA has higher upside potential than Innate Pharma SA, analysts believe Cellectis SA is more attractive than Innate Pharma SA.
Company Buy Ratings Hold Ratings Sell Ratings IPHAInnate Pharma SA2 1 0 CLLSCellectis SA0 0 0 -
Is IPHA or CLLS More Risky?
Innate Pharma SA has a beta of 0.290, which suggesting that the stock is 71.016% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.093, suggesting its more volatile than the S&P 500 by 209.338%.
-
Which is a Better Dividend Stock IPHA or CLLS?
Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IPHA or CLLS?
Innate Pharma SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $16.2M. Innate Pharma SA's net income of -- is lower than Cellectis SA's net income of -$23.1M. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 6.15x versus 4.96x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPHAInnate Pharma SA6.15x -- -- -- CLLSCellectis SA4.96x -- $16.2M -$23.1M
-
Which has Higher Returns IPHA or DBVT?
DBV Technologies SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IPHAInnate Pharma SA-- -- $68.9M DBVTDBV Technologies SA-- -$1.60 -- -
What do Analysts Say About IPHA or DBVT?
Innate Pharma SA has a consensus price target of $7.25, signalling upside risk potential of 263.33%. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 590.04%. Given that DBV Technologies SA has higher upside potential than Innate Pharma SA, analysts believe DBV Technologies SA is more attractive than Innate Pharma SA.
Company Buy Ratings Hold Ratings Sell Ratings IPHAInnate Pharma SA2 1 0 DBVTDBV Technologies SA0 0 0 -
Is IPHA or DBVT More Risky?
Innate Pharma SA has a beta of 0.290, which suggesting that the stock is 71.016% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.
-
Which is a Better Dividend Stock IPHA or DBVT?
Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IPHA or DBVT?
Innate Pharma SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than DBV Technologies SA's net income of -$30.4M. Notably, Innate Pharma SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 6.15x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPHAInnate Pharma SA6.15x -- -- -- DBVTDBV Technologies SA-- -- -- -$30.4M
-
Which has Higher Returns IPHA or GNFT?
Genfit SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Genfit SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IPHAInnate Pharma SA-- -- $68.9M GNFTGenfit SA-- -- -- -
What do Analysts Say About IPHA or GNFT?
Innate Pharma SA has a consensus price target of $7.25, signalling upside risk potential of 263.33%. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could grow by 170.55%. Given that Innate Pharma SA has higher upside potential than Genfit SA, analysts believe Innate Pharma SA is more attractive than Genfit SA.
Company Buy Ratings Hold Ratings Sell Ratings IPHAInnate Pharma SA2 1 0 GNFTGenfit SA0 0 0 -
Is IPHA or GNFT More Risky?
Innate Pharma SA has a beta of 0.290, which suggesting that the stock is 71.016% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.145, suggesting its more volatile than the S&P 500 by 14.458%.
-
Which is a Better Dividend Stock IPHA or GNFT?
Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IPHA or GNFT?
Innate Pharma SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Genfit SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 33.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 6.15x versus 2.75x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPHAInnate Pharma SA6.15x -- -- -- GNFTGenfit SA2.75x 33.72x -- --
-
Which has Higher Returns IPHA or IVA?
Inventiva SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Inventiva SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IPHAInnate Pharma SA-- -- $68.9M IVAInventiva SA-- -- -$34.6M -
What do Analysts Say About IPHA or IVA?
Innate Pharma SA has a consensus price target of $7.25, signalling upside risk potential of 263.33%. On the other hand Inventiva SA has an analysts' consensus of -- which suggests that it could grow by 429.11%. Given that Inventiva SA has higher upside potential than Innate Pharma SA, analysts believe Inventiva SA is more attractive than Innate Pharma SA.
Company Buy Ratings Hold Ratings Sell Ratings IPHAInnate Pharma SA2 1 0 IVAInventiva SA0 0 0 -
Is IPHA or IVA More Risky?
Innate Pharma SA has a beta of 0.290, which suggesting that the stock is 71.016% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IPHA or IVA?
Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IPHA or IVA?
Innate Pharma SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Inventiva SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 6.15x versus 7.03x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPHAInnate Pharma SA6.15x -- -- -- IVAInventiva SA7.03x -- -- --
-
Which has Higher Returns IPHA or NBTX?
Nanobiotix SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Nanobiotix SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IPHAInnate Pharma SA-- -- $68.9M NBTXNanobiotix SA-- -- $24.3M -
What do Analysts Say About IPHA or NBTX?
Innate Pharma SA has a consensus price target of $7.25, signalling upside risk potential of 263.33%. On the other hand Nanobiotix SA has an analysts' consensus of $10.31 which suggests that it could grow by 229.53%. Given that Innate Pharma SA has higher upside potential than Nanobiotix SA, analysts believe Innate Pharma SA is more attractive than Nanobiotix SA.
Company Buy Ratings Hold Ratings Sell Ratings IPHAInnate Pharma SA2 1 0 NBTXNanobiotix SA3 0 0 -
Is IPHA or NBTX More Risky?
Innate Pharma SA has a beta of 0.290, which suggesting that the stock is 71.016% less volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IPHA or NBTX?
Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IPHA or NBTX?
Innate Pharma SA quarterly revenues are --, which are smaller than Nanobiotix SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Nanobiotix SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 6.15x versus 3.45x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IPHAInnate Pharma SA6.15x -- -- -- NBTXNanobiotix SA3.45x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
